MONTRÉAL, July 3, 2025 – In June, both Canada’s Drug Agency (CDA) and Quebec’s Institut national d’excellence en santé et en services sociaux (INESSS) released...
The CHS is very proud to present its latest publication, the first component of its brand-new Novel Therapies Education Program. CLICK HERE to access the online booklet.
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...
SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...